AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Tcitib Tablet ER

Prescription Icon
Prescription Required

Marketer

Akumentis Healthcare Ltd

Salt Composition

Tofacitinib (11mg)

Overview Tcitib Tablet ER

Extended-release Tcitib tablets manage moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. They alleviate joint pain, tenderness, and swelling by suppressing inflammation, also slowing joint and bone deterioration. Tcitib ER may be prescribed alone or with other medications. These tablets can be taken with or without food, ideally at the same time daily. Dosage depends on your condition and other medications. Always follow your physician's instructions; abruptly stopping treatment could worsen your condition. Common side effects include upper respiratory infections, headaches, diarrhea, and nasopharyngitis. Less frequent, but potentially serious, side effects—including blood clots and gastrointestinal perforation—require immediate medical attention. Report any concerns to your doctor. Pre-treatment blood tests may be necessary. Do not commence treatment with any infection. Inform your doctor of any history of tuberculosis, herpes zoster (shingles), kidney or liver disease, hepatitis B or C, or pulmonary or leg blood clots. Tcitib ER increases infection susceptibility; avoid contact with contagious individuals (e.g., those with chickenpox, measles, or influenza). This medication is unsuitable for individuals under 18 or those who are pregnant or breastfeeding, unless deemed beneficial by your physician. Regular checkups may be required.

Uses of Tcitib Tablet ER

Management of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

Major Benefits of Tcitib Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for Tcitib Tablet ER. Ingest the tablet whole; avoid chewing, crushing, or breaking it. This medication can be administered with or without food, but consistent timing is recommended.

Common Side effects of Tcitib Tablet ER:

  • Upper respiratory tract infection
  • Headache
  • Diarrhea
  • Nasopharyngitis (inflammation of the throat and nasal passages)

How to use Tcitib Tablet ER:

Administer this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Tcitib Extended-Release Tablets can be consumed with or without food, although consistent timing is recommended.

How Tcitib Tablet ER works:

Extended-release Tcitib tablets function as a Janus kinase inhibitor, suppressing Janus kinase enzyme activity. This consequently reduces immune system activity and inflammation characteristic of rheumatic conditions and ulcerative colitis.

SAFETY ADVICE

AlcoholAlcoholSAFE

There are no known adverse reactions associated with the concomitant use of Tcitib Tablet ER and alcohol.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Tcitib tablets might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any possible dangers prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Tcitib tablets are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingSAFE

Driving ability is typically unaffected by Tcitib Extended-Release Tablets.

KidneyKidneyCAUTION

Patients with severe kidney impairment should exercise caution when using extended-release Tcitib tablets. Dosage modification of extended-release Tcitib may be necessary; physician consultation is advised.

LiverLiverCAUTION

Patients with severe hepatic impairment should use Tcitib Extended-Release tablets cautiously. Dosage modification of Tcitib Extended-Release tablets may be necessary; physician consultation is advised.

What if you forget to take Tcitib Tablet ER :

Should you forget a dose of Tcitib Tablet ER, administer it at your earliest convenience. However, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Tcitib Tablet ER

LabelValue
Type of Compound Pyrrolopyrimidine-based compound
Potential for Dependence None.
Medication Classification Pain relievers
Mechanism of Action JAK inhibitors

FAQs on Tcitib Tablet ER

Consult your physician regarding any pre-existing liver conditions prior to commencing treatment with Tcitib Tablet ER. This precaution is necessary as Tcitib Tablet ER may elevate liver enzyme levels in some individuals. Consequently, a liver function assessment is recommended before initiating Tcitib Tablet ER therapy. While Tcitib Tablet ER may be administered to patients with mild to moderate hepatic impairment, its use is contraindicated in those with severe liver dysfunction.
Extended-release Tcitib tablets can elevate the likelihood of various cancers, such as lymphoma and skin cancers, by impacting immune function. Therefore, disclose any history of cancer to your physician.
Tcitib Extended-Release tablets are indicated for patients with moderate to severe rheumatoid arthritis, a joint inflammatory disorder. This medication is prescribed when prior treatments proved ineffective or unsuitable. Alternatively, it may be initiated earlier in the treatment course if the patient exhibits a poor response to initial medications. Tcitib may be administered as monotherapy or in conjunction with other drugs, including methotrexate.
The full therapeutic benefit of Tcitib Extended-Release tablets typically becomes apparent within 3 to 6 months, although some improvement may be noticed as early as 2 to 8 weeks after starting treatment.
Prior to commencing or during treatment with Tcitib Tablet ER, blood work may be necessary. These tests assess for anemia (low red blood cell count), neutropenia or lymphopenia (low white blood cell count), elevated cholesterol (high blood fat), and abnormal liver enzyme levels. This monitoring helps determine if Tcitib Tablet ER is causing adverse effects. Furthermore, pre-treatment tuberculosis screening may be recommended, as Tcitib Tablet ER could exacerbate any existing infection.
Tcitib Extended-Release tablets modulate the immune system. This can weaken the body's defense against infections, raising the likelihood of severe infections, such as tuberculosis. These infections may be caused by serious fungi, bacteria, or viruses that disseminate systemically. Such infections can be fatal, necessitating inpatient treatment.
Concurrent use of tocilizumab and Tcitib Tablet ER is contraindicated. Tcitib Tablet ER's immunosuppressive properties necessitate avoidance of concomitant administration with other immune-modulating drugs. This combination elevates infection risk and potentially precipitates adverse events.
Tcitib Tablet ER
451
MRP 550
18% off